Praxis Precision Medicines, Inc. ((PRAX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Praxis Precision Medicines, Inc. is conducting a Phase 2 clinical trial titled ‘A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE).’ The study aims to assess the safety, tolerability, efficacy, and pharmacokinetics of PRAX-562 in pediatric patients with SCN2A and SCN8A encephalopathies, conditions characterized by early-onset seizures.
The intervention being tested is PRAX-562, an experimental drug administered either orally or via gastrostomy tube. The treatment is designed to manage seizures associated with developmental and epileptic encephalopathies.
This study is interventional, with participants randomly assigned to different treatment groups in a parallel design. It employs a triple-masking approach, ensuring that participants, care providers, and investigators are unaware of group assignments. The primary purpose is to evaluate treatment efficacy.
The study began on March 17, 2023, with an estimated primary completion date in 2025. The latest update was submitted on January 24, 2025, indicating ongoing recruitment and progress.
The outcome of this trial could significantly influence Praxis Precision Medicines’ stock performance and investor sentiment, given the potential market for effective treatments for rare epileptic conditions. Competitors in the neurological drug market may also be affected by the results.
The study is currently ongoing, with further details available on the ClinicalTrials portal.